TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT03453983

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Transcrainial Direct Current Stimulation (tDCS)
Description: Transcranial direct current stimulation (tDCS) is a safe non-invasive form of brain stimulation, which modulates, through the application of weak direct current, cortical excitability. The applied subthreshold current passes through two externally placed electrodes, an anode and cathode.

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Transcrainial Direct Current Stimulation (tDCS)
Description: Transcranial direct current stimulation (tDCS) is a safe non-invasive form of brain stimulation, which modulates, through the application of weak direct current, cortical excitability. The applied subthreshold current passes through two externally placed electrodes, an anode and cathode.
Study: NCT02474082

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Secukinumab
Description: Secukinumab 150 mg, 1 ml liquid formulation in a pre-filled pen for s.c. injection

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Fumaric acid
Description: Fumaric acid initial therapy (tablet contains 30 mg dimethylfumarate, 67 mg ethylhydrogenfumarate calcium salt, 5 mg ethylhydrogenfumarate magnesium salt, 3 mg ethylhydrogenfumarate zinc salt) and Fumaric acid maintenance therapy (tablet contains 120 mg dimethylfumarate, 87 mg ethylhydrogenfumarate calcium salt, 5 mg ethylhydrogenfumarate magnesium salt, 3 mg ethylhydrogenfumarate zinc salt)
Study: NCT01841333

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PF-04449913
Description: 100mg given orally
Study: NCT02883751

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: LED
Description: A device with 36, rectangular, red LEDs, registered with the Brazilian National Health Surveillance Agency (ANVISA authorization nº 8.04554.6), λ = (650 ± 20) nm, with an output power of 324 mW and an output area of 2.54 cm2 (Cosmedical, Brazil), will be enveloped with sterile, disposable, plastic wrap (transparent in the red wavelength) to permit contact with the skin for ten minutes during each session. The plastic wrap will be changed after each use. The amount of energy delivered will be 194.4 J.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Control group
Description: Conventional ulcer treatment with rayon® (Polar Fix, Polar Fix, Mauá, SP, Brazil) and essential fatty acids (Dersani®, Saniplan, Daudt, São Paulo, SP, Brazil) (composition: decanoic acid, caprylic acid, hexanoic acid, lauric acid, linoleic acid, lecithin, retinyl palmitate, tocopheryl acetate and alpha-tocopheryl).
Study: NCT00553163

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Gut focussed hypnotherapy
Description: Gut focussed hypnotherapy

Intervention type: BEHAVIORAL
Group type: SHAM_COMPARATOR
Intervention: Control educational sessions
Description: Control educational sessions
Study: NCT01934088

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Propofol

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Midazolam

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Fentanyl
Study: NCT03754309

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: KY1005
Description: A human anti-OX40 ligand monoclonal antibody

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: KY1005
Description: A human anti-OX40 ligand monoclonal antibody

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Matched placebo
Study: NCT00918151

Intervention type: OTHER
Intervention: No treatment given
Description: Subject will only fill out a questionaire when entering the observational study
Study: NCT05151055

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Lactezin
Description: 100 mg lactoferrin, 11 IU vitamin E (as alpha tocopherol), and 5 mg zinc (as zinc gluconate)

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: starch
Study: NCT03750266

Intervention type: OTHER
Intervention: No intervention data collected through routine scans
Description: No intervention, we wish to use the images a mother would have done as part of her normal medical care and make both 3D animations and 3D models of the baby and it's CDH.
Study: NCT01286246

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vaginal progesterone
Description: Capsules of 200mg micronised progesterone suspended in sunflower oil. One capsule inserted vaginally per day from time of randomisation to gestational age 35(+6)weeks or delivery (if sooner).

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Capsules of placebo (sunflower oil). One capsule inserted vaginally per day from time of randomisation to gestational age 35(+6)weeks or delivery (if sooner).
Study: NCT01367522

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SC Methylnaltrexone (MNTX)
Study: NCT00733707

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Text messaging reminders
Description: Subjects in this arm will receive daily text message reminders once per day at the same time each day. Messages will remind the subject to take their oral contraceptive pill.
Study: NCT01948843

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ADI-PEG 20
Study: NCT00887393

Intervention type: OTHER
Group type: OTHER
Intervention: low carbohydrate diet
Description: 1000 to 1200 kcalorie low carbohydrate diet (\< 15% of total kcaloric intake)

Intervention type: OTHER
Group type: OTHER
Intervention: low-fat diet
Description: 1000 to 1200 kcalorie low-fat diet (30% fat, 60% carbohydrates of total kcaloric intake)
Study: NCT03557281

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GSK3036656
Description: GSK3036656 will be administered

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GSK3036656
Description: GSK3036656 will be administered

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GSK3036656
Description: GSK3036656 will be administered
Study: NCT01393288

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Ondansetron
Description: 8 mg ondansetron ODT or placebo, 1 hour pre-operatively, before discharge, evening of day of surgery, morning of postoperative day (POD) 1, lunch POD 1, evening POD 1, and morning of POD 2
Study: NCT03557281

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GSK3036656
Description: GSK3036656 will be administered

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Rifafour e-275
Description: Rifafour e-275 will be administered
Study: NCT02198807

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fosmidomycin-Piperaquine
Study: NCT02077088

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: galactooligosaccharide
Description: addition of food grade GRAS (Generally Regarded As Safe) galactooligosaccharides
Study: NCT02381665

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Flexstim IF
Description: Patient enrolled will receive a device for effective interferential current stimulation

Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Flexstim IF faked
Description: Patient enrolled will receive a sham device.
Study: NCT01382732

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carbetocin
Description: Protocol A (carbetocin + placebo) Carbetocin: 100ug (1mL) + Ringer's Lactate 10mL directly into the vein in no less than two minutes.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Oxytocin
Description: Oxytocin 20 U (4mL) diluted in a bag with 1000mL of Ringer's Lactate to be passed intravenously at a rate of 125mL/hr
Study: NCT01849770

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Mexiletine

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Mexiletine

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study: NCT03501030

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Activity restriction
Description: Women in the intervention group will be recommended activity restriction. Activity restriction is defined as the following forms of activity restriction: pelvic rest and prohibition of sexual activity, reduction of work and/or non work activity. Bed rest will not recommended.
Study: NCT02511652

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Ambu AuraGain evaluation
Description: Evaluation of clinical performance in terms of Insertion, ventilation, position and complications

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: LMA Supreme evaluation
Description: Evaluation of clinical performance in terms of Insertion, ventilation, position and complications

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Laparoscopic surgery
Description: Gynecologic laparoscopic surgery in the trendelemburg position

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Laparoscopic surgery
Description: Gynecologic laparoscopic surgery in the trendelemburg position
Study: NCT04173429

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nadroparin calcium, warfarin
Description: Nadroparin calcium subcutaneously every 12hs for 1 months followed by warfarin orally for 5 months. INR(international normalized ratio ) was detected every 3-4 days and adjusted carefully by 0.75mg dosage until achieve the target level of 2-3.
Study: NCT01511770

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fluconazole
Description: Fluconazole Tablets, 200 mg

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Fluconazole
Description: Fluconazole 200 mg tablets
Study: NCT00865865

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Computer aided total knee arthroplasty
Description: Use of computer aided surgery to balance soft tissue tension in total knee arthroplasty

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Conventional total knee arthroplasty
Description: Conventional method of total knee arthroplasty
Study: NCT01157039

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Glutamine
Description: Glutamine- During the first cycle of oxaliplatin based combination therapy (mFOLFOX 6 or XELOX) no patient will receive glutamine. At cycle 2, patients will be randomized to receive for 6 days either : Glutamine 30g/day during cycle 2 and glutamine 40g/day during cycle 3 (ARM A) or glutamine 40g/day at cycle 2 and glutamine 30g/day at cycle 3 (Arm B).

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Glutamine
Description: Glutamine- During the first cycle of oxaliplatin based combination therapy (mFOLFOX 6 or XELOX) no patient will receive glutamine. At cycle 2, patients will be randomized to receive for 6 days either : Glutamine 30g/day during cycle 2 and glutamine 40g/day during cycle 3 (ARM A) or glutamine 40g/day at cycle 2 and glutamine 30g/day at cycle 3 (Arm B).
Study: NCT03242837

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Army Resilience Training
Description: The Army Resilience Training consists four training sessions of 90 minutes each. Participants learn to reflect their stress management (including thinking, emotions, behavioral consequences; coping strategies) and build resilience using specific strategies.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Diversity Management Training
Description: Diversity Management Training consists four training sessions of 90 minutes each. Participants learn about diversity and social awareness reflecting different situations and settings.
Study: NCT03403205

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ALXN1840
Description: ALXN1840 administered orally in 15 mg tablets

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: SoC Therapy
Description: Depending on the site/region, participants randomized to receive SoC treatment will receive trientine, penicillamine, Zinc, or a combination of these medicines, administered according to standard regimens.
Study: NCT03506295

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Radial Endobronchial Ultrasound Probe
Description: The radial EBUS procedure is performed by inserting a miniature ultrasound probe (radial EBUS probe) through the working channel of a flexible bronchoscope or catheter (guide sheath). Real-time imaging of the surrounding tissue enables the clinician to determine the lesion's exact location and size.

Intervention type: DEVICE
Group type: OTHER
Intervention: Flouroscopy
Description: Real-time fluoroscopy will be used in all cases to guide the radial probe ultrasound and/or cryobiopsy probe placement.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Flouroscopy
Description: Real-time fluoroscopy will be used in all cases to guide the radial probe ultrasound and/or cryobiopsy probe placement.
Study: NCT02575287

Intervention type: DEVICE
Intervention: Optical Enhancement
Description: A endoscopic visualization of the mucosa using the pre-processor filter called Optical enhancement (Pentax Video Processor EPK-i7010; HOYA Co. Tokyo, Japan)

Intervention type: DEVICE
Intervention: Optical Enhancement
Description: A endoscopic visualization of the mucosa using the pre-processor filter called Optical enhancement (Pentax Video Processor EPK-i7010; HOYA Co. Tokyo, Japan)

Intervention type: DEVICE
Intervention: Optical Enhancement with optical magnification
Description: A endoscopic visualization of the mucosa using the pre-processor filter called Optical enhancement associated with an optical magnification using the scope called magniview (PENTAX Medical EG-2990Zi)

Intervention type: DEVICE
Intervention: Optical Enhancement with optical magnification
Description: A endoscopic visualization of the mucosa using the pre-processor filter called Optical enhancement associated with an optical magnification using the scope called magniview (PENTAX Medical EG-2990Zi)

Intervention type: DEVICE
Intervention: Optical magnification without Optical enhancement
Description: A endoscopic visualization of the mucosa using optical magnification without the use of the pre-processor filter called Optical enhancement

Intervention type: DEVICE
Intervention: Optical magnification without Optical enhancement
Description: A endoscopic visualization of the mucosa using optical magnification without the use of the pre-processor filter called Optical enhancement
Study: NCT01938144

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Advil Congestion Relief
Description: Orally adminstered, 200 mg Ibuprofen/10 mg Phenylephrine tablet, 4x/day, up to 8 doses.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Advil Allergy and Congestion Relief
Description: Orally adminstered, 200 mg Ibuprofen/10 mg Phenylephrine/4 mg Chlorpheniramine tablet, 4x/day, up to 8 doses.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Paracetamol
Description: Acetaminophen 500 mg, 4x/day, up to 8 doses.
Study: NCT00853697

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: testosterone (AndroGel®) with the 5α-reductase inhibitor dutasteride
Description: Patients will be treated with dutasteride 3.5 mg once daily (oral administration). To avoid rapid conversion of testosterone to DHT in case 5α-reductase is not adequately inhibited during the first few days of concurrent treatment with dutasteride and testosterone, daily dutasteride treatment will be initiated 7 days prior to testosterone initiation.~Patients will receive AndroGel® at the dose of 15 g (3 times the standard replacement dose for hypogonadism) once daily (topical administration), starting on Day 8 and continuing for 12 weeks (or until disease progression or withdrawal from the study).
Study: NCT01393288

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Lorazepam
Description: 1 mg Lorazepam or placebo 1 hour preoperatively, before discharge, evening of day of surgery, morning of postoperative day (POD) 1, lunch of POD 1, evening of POD 1, and morning of POD 2.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Aprepitant
Description: 40 mg Aprepitant or placebo 1 hour preoperatively and before discharge (placebo for postoperative days 1-2)
Study: NCT03682978

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Arbaclofen
Description: Arbaclofen tablet.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo tablet.
Study: NCT02576743

Intervention type: DEVICE
Intervention: 7 Tesla MRI
Description: MR imaging using a 7 Tesla MR system.

Intervention type: DEVICE
Intervention: 7 Tesla MRI
Description: MR imaging using a 7 Tesla MR system.
Study: NCT04481776

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Breakfast consumption
Description: Standardised breakfast consumption across seven days

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Breakfast omission
Description: No breakfast consumed across seven days
Study: NCT03175549

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Apremilast
Description: Fixed oral dose of 90 mg/d following the standard titration for a total dosing duration of 14 days.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Identical placebo pills taken orally for 14 days
Study: NCT03188237

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: AfyaJamii
Description: AfyaJamii is a group antenatal and well-child care program developed in Kenya for use in Kenyan health centers
Study: NCT00513760

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Grapefruit juice
Description: Coingestion of 240 ml of grapefruit juice with 10 mg of montelukast.

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Orange Juice
Description: Coingestion of 240 ml of orange juice with 10 mg of montelukast.

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Gatorade
Description: Coingestion of 240 ml of Gatorade with 10 mg of montelukast.
Study: NCT00391222

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Olanzapine
Description: Intramuscular injections of placebo every 2 weeks and oral olanzapine 10 mg daily

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Intramuscular injections of placebo every 2 weeks and oral placebo daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Risperidone Long Acting Injectable (LAI)
Description: Intramuscular injections of risperidone LAI (25, 37.5, or 50 mg) every 2 weeks and oral placebo daily
Study: NCT03201185

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ramipril
Description: Initial dose: 2,5 mg. Up-titrated at one month to 5 mg and 10 mg at three months (following clinical practice recommendations for up-titration). Target dose: 10 mg (or maximum tolerated dose).
Study: NCT03046355

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Labor induction at 37.0 to 37.6 weeks of gestation
Description: Diagnosis of FGR with induction at 37 weeks 0 days of gestation to 37 weeks and 6 days

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Expectant monitoring until delivery
Description: Diagnosis of FGR managed with expectant monitoring and delivery as indicated
Study: NCT03642678

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: ONS
Description: High-risk patients identified by prediction model in study group are intervened by pre-defined intervention protocol, which include oral nutrition supply, infection prevention, bp control and improving of dialysis therapy options and so on.
Study: NCT02903680

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dexamethasone group
Description: The intervention of interest was the administration of dexamethasone 0.6 mg/kg IV (max 15 mg) before departure from the ED. The control group received a similar looking placebo (NaCl 0,9% IV) with the same volume.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo group
Description: Normal Saline 0,9% same volume
Study: NCT03823612

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Clinpro Tooth Creme
Description: The participant will be instructed to Place a pea-sized amount of Clinpro Tooth Crème on a soft bristled toothbrush and brush teeth for at least two minutes then after brushing the patient will rinse out his mouth with water and spit out. It will be used twice daily at first in the morning and before sleep.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GC tooth mousse
Description: The participant will be instructed to squeeze a small amount of GC Tooth Mousse out onto a clean finger. A cotton tip, swab or custom tray are suitable application methods as it will Applied directly onto his tooth surfaces and leave undisturbed for three minutes then he will be instructed to Spread any residual crème around the mouth with his tongue and hold for a further one to two minutes then the participant will expectorate thoroughly and if possible he should avoid rinsing. Any GC Tooth Mousse remaining in the mouth can be left to gradually dissipate. The participant will be instructed to avoid eating or drinking for 30 minutes following application.
Study: NCT03665142

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Kinesio taping
Description: Upper trapezius muscle stretching exercise with Kinesio taping (KT) was applied to the study group. KT was applied 8 times in total for 4 weeks with 2 sessions per week. Stretching exercise was done in the morning, afternoon and evening 3 times (repeated 10 times per set) every day for 4 weeks and 5 days of the week.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Exercise
Description: Upper trapezius muscle stretching exercise was applied to the control group.
Study: NCT03680495

Intervention type: DRUG
Intervention: Methylprednisolone
Description: 1. Methylprednisolone is a steroid (corticosteroid) similar to a product produced in the adrenal glands. It is used to help relieve inflammation (swelling, heat, redness, and pain) and is used to treat certain medical issues including COPD.

Intervention type: DRUG
Intervention: Methylprednisolone
Description: 1. Methylprednisolone is a steroid (corticosteroid) similar to a product produced in the adrenal glands. It is used to help relieve inflammation (swelling, heat, redness, and pain) and is used to treat certain medical issues including COPD.
Study: NCT02727283

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GSK3179106
Description: GSK3179106 will be provided as white to slightly colored round or oblong tablet for oral administration with unit dose strength of 5 mg, 25 mg and 100 mg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GSK3179106
Description: GSK3179106 will be provided as white to slightly colored round or oblong tablet for oral administration with unit dose strength of 5 mg, 25 mg and 100 mg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo will be provided as white to slightly colored round or oblong tablet for oral administration with unit dose strength to match actives across all strengths

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo will be provided as white to slightly colored round or oblong tablet for oral administration with unit dose strength to match actives across all strengths